We have studied the in vitro actions of the sesquiterpene lactone parthenolide (PTL) on cells isolated from patients with chronic lymphocytic leukemia (CLL). Dye reduction viability assays showed that the median LD 50 for PTL was 6.2 lM (n ¼ 78). Fifteen of these isolates were relatively resistant to the conventional agent chlorambucil but retained sensitivity to PTL. Brief exposures to PTL (1-3 h) were sufficient to induce caspase activation and commitment to cell death. Chronic lymphocytic leukemia cells were more sensitive towards PTL than were normal T lymphocytes or CD34
Introduction
In B-chronic lymphocytic leukemia (CLL) the CD5 þ CD19 þ malignant clone accumulates relentlessly by evading apoptotic cell death. 1 Chronic lymphocytic leukemia comprises two major subtypes with widely differing clinical outcomes. Approximately, two-third of cases constitute a good prognosis group, characterized by relatively hypermutated immunoglobulin heavy chain variable (IgV H ) gene segments. In contrast, the remaining one-third of patients, with relatively unmutated IgV H genes, show a poor prognosis, with a rapidly progressing and usually fatal course.
Chlorambucil has, for many years, been the drug of choice for CLL treatment. The more recent introduction of the nucleoside analog fludarabine has resulted in increased remission rates. 2 However, fludarabine monotherapy has not improved overall survival. Furthermore, fludarabine is highly toxic to T lymphocytes, thus increasing the incidence of opportunistic infections owing to the prolonged depression of CD4 þ T cells. 3, 4 The gradual evolution of drug resistance as a consequence of treatment with DNA-damaging agents additionally limits their therapeutic utility. Killing of CLL cells by these agents may be mediated via upregulation of the proapoptotic transcription factor p53. 5 A substantial proportion of poor prognosis patients harbour defects either in the p53 gene itself or in the gene encoding the ATM protein kinase, which mediates p53 upregulation in response to DNA damage. 6, 7 Therefore, there is a need to identify novel agents active against CLL, preferably by a p53-independent mechanism, particularly for treatment of the poor prognosis patients who are less likely to respond to conventional drugs. 8 Recent studies have therefore focused on drugs that induce CLL cell killing via direct interaction with novel cellular targets involved in apoptosis regulation. [9] [10] [11] [12] There has also been considerable interest in natural products active against CLL cells, including the green tea polyphenol epigallocatechin-3-gallate 13 and the bacterial metabolite prodigiosin. 14 The sesquiterpene lactone parthenolide (PTL) has been widely used in traditional medicine for the treatment of migraines and inflammation. 15 This compound has recently been shown to induce apoptosis of hepatoma 16, 17 and cholangiocarcinoma 18 cell lines and of primary acute and chronic myeloid leukemia cells 19 in vitro, with IC 50 values varying between 5 and 20 mM. The killing of hepatoma 16 and myeloid leukemia 19 cells was dependent on the PTL-induced generation of reactive oxygen species (ROS). Other studies have shown that PTL targets the antiapoptotic transcription factor nuclear factor-kappa B (NFkB) via inhibition of the upstream regulator inhibitor of kB (IkB) kinase (IKK), 20 which phosphorylates IkB and targets it for proteasomal degradation.
Here, we have investigated the actions of PTL on cells isolated from CLL patients. We show for the first time that brief exposure to PTL selectively induces commitment of CLL cells to apoptosis at concentrations that caused minimal killing in normal T lymphocytes and bone marrow haematopoietic progenitors. This is the first report on the actions of sesquiterpene lactones on CLL cells. Some of the data have been presented here in preliminary form (AJ Steele et al. Blood 2004; 104: 949a-949b; abstract).
Materials and methods
Sources of reagents, patient data, procedures for purification and culture of CLL and normal blood cells, Western blot and electrophoretic mobility shift assay (EMSA) protocols and statistical methods are described in a Supplementary Information.
Determination of cell killing
Cytotoxicity was assessed by carrying out triplicate assays for the reduction of 3-4,5-dimethylthiazol-2,5-diphenyl tetrazolium bromide (MTT) 21 following 24 h incubation of cells with serial twofold dilutions of drugs. LD 50 values were computed using Calcusyn software (Biosoft, Ferguson, MO, USA).
Flow cytometric analysis of cell killing
Cells (5 Â 10 6 /ml) were exposed to 2, 5 or 20 mM PTL for 24 h. Cell death was evaluated by flow cytometric analysis of annexin V-stained cells as described. 22 Agent-specific cell death was computed using a published equation: 23 Agent À specific death ¼ % annexin À positive cells induced by agent À % annexin À positive cells in untreated control=100 À % annexin À positive cells in untreated control:
Differential detergent fractionation
Chronic lymphocytic leukemia cells were resolved into cytosolic, membrane/organelle and soluble nuclear fractions by differential detergent fractionation (DDF). 24 
Immunoprecipitation of activated Bax
The activated conformation of the Bax protein was immunocaptured using the Bax 6A7 antibody (BD PharMingen, Cowley, Oxford, UK) essentially as described. 25 
Measurement of reactive oxygen species generation
Reactive oxygen species generation was detected by quantifying the fluorescence of cells incubated with 5-(-6)-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate acetyl ester (CM-H 2 DCFDA; Invitrogen). Chronic lymphocytic leukemia cells (5 Â 10 6 /ml) were incubated at 371C with 10 mM CM-H 2 DCFDA for 45 min. The cells were centrifuged at 700 Â g for 3 min and re-suspended in RPMI 1640 medium containing 10% fetal calf serum at 1 Â 10 6 cells/ml. Half the cells were treated with 20 mM N-acetylcysteine (NAC) for 1 h. The cells were then treated with PTL for a further 1 h. Cells were centrifuged, washed twice with pre-warmed phosphate-buffered saline (PBS) and re-suspended in 300 ml PBS and analysed using a FACScan instrument (Becton Dickinson, Oxford, UK). Histograms were generated showing the number of events versus CM-H 2 DCFDA fluorescence.
Results and discussion

Rapid induction of chronic lymphocytic leukemia apoptosis by parthenolide
The 24 h PTL LD 50 values for 78 CLL isolates are shown in Figure 1a . The median LD 50 for this CLL cohort was 6.2 mM. The LD 50 for 36 isolates was below 5 mM, between 5 and 10 mM for 25 isolates and between 10 and 20 mM for 13 isolates. Four samples were relatively resistant to this agent, with an LD 50 values in excess of 20 mM. We observed no significant difference between the median LD 50 values for PTL determined for the IgV H mutated (6.3 mM) and the IgV H unmutated (5.8 mM) groups (P ¼ 0.678), implying that PTL is equally effective at inducing apoptotic death of CLL cells irrespective of the prognostic group 1 of the patient. The median LD 50 value for the CLL isolates (6.2 mM) is comparable to the PTL concentrations required for half-maximal killing of acute and chronic myeloid leukemia cells following a 24-h incubation. 19 LD 50 values of 10-20 mM were observed for cholangiocarcinoma cells following 72 h incubations. 18 For comparison, we determined that the median LD 50 for 12 CLL isolates following this longer incubation was 3.7 mM. Therefore, CLL cells were more susceptible to killing by PTL than were cholangiocarcinoma cells.
The LD 50 values for PTL were compared with LD 50 values for chlorambucil (CHL) (Figure 1b) . We observed no correlation between the sensitivities of individual isolates towards PTL and CHL (R 2 ¼ 0.15). A subset of 15 isolates requiring 4200 mM CHL to secure 50% killing showed LD 50 values for PTL of less than 15 mM (Figure 1b , dashed pentagon), suggesting that isolates relatively resistant to CHL may nevertheless retain sensitivity to PTL.
Activation of apoptotic cell death requires activation of the cysteine protease caspase 3. 26 We therefore determined the time course of PTL-induced apoptosis by Western blot quantitation of cleavage of the 116 kDa caspase 3 substrate poly (ADP ribose) polymerase (p116 PARP) to an 85 kDa fragment (p85 PARP). PARP cleavage in cells treated with 7.5 or 20 mM PTL was rapid, being detectable by 3 h incubation ( Figure 2a) . Following 6 h incubation, greater than 50% PARP cleavage was observed in cells treated with either concentration of the drug. In this isolate, a lower but clearly detectable level of the p85 fragment was We then used the criterion of PARP cleavage to determine the minimum PTL exposure time required to secure commitment to apoptosis (Figure 2b ). Pulse incubation of CLL cells with 20 mM PTL for a period as short as 1 h resulted in a level of PARP cleavage, quantified at 6 h, that was essentially indistinguishable from that achieved following 6 h continuous incubation with the same drug concentration. At lower concentrations of PTL (2.5 or 7.5 mM), a 3-h pulse of the drug was sufficient to secure PARP cleavage equivalent to that observed following 6 h continuous incubation with the same drug concentrations (Figure 2b ).
Chronic lymphocytic leukemia cells are more sensitive to parthenolide than are normal T lymphocytes or haematopoietic progenitors
We compared the PTL sensitivity of CLL cells with that of normal lymphocytes and CD34 þ haematopoietic progenitors. Using annexin V positivity to quantify apoptotic cells, 22, 23 we observed that 6 h exposures to 2 or 7.5 mM PTL, followed by washing and further incubation for 18 h in drug-free medium, resulted in substantially greater killing of CLL cells relative to T and B lymphocytes and CD34 þ cells immunomagnetically purified from normal control subjects (Figure 3a) . However, the killing of B cells and CD34 þ progenitors induced by 20 mM PTL approached the level of death induced by treatment of CLL cells with the same drug concentration, whereas normal T cells were slightly less susceptible. 3-4,5-Dimethylthiazol-2,5-diphenyl tetrazolium bromide assay following 24 h incubation with increasing concentrations of PTL showed that, under these conditions, T cells were resistant up to 10 mM PTL. In contrast, B cells showed an LD 50 value very similar to the median LD 50 value for CLL cells (see Supplementary Figure 1) .
The actions of PTL on haematopoietic progenitors was additionally determined by incubation of normal bone marrow cells with PTL, followed by washing and incubation in a 14-day colony assay. The ability of the progenitors to form haematopoietic colonies was essentially unaffected by 6 h exposure to 7.5 mM PTL, whereas incubation with 20 mM of the drug resulted in a modest (31%) though statistically significant impairment (Figure 3d) , essentially confirming the observations of Guzman et al. Taken together, the data suggest that CLL cells and normal B cells were similarly sensitive to PTL. Importantly, normal T cells and haematopoietic progenitors were substantially less sensitive to PTL than were CLL cells. The rapid commitment of CLL cells to PTL-induced apoptosis (Figure 2b ), together with its target cell selectivity, may allow the development of appropriate protocols that secure selective killing of malignant CLL cells in a clinical setting, with minimal actions on normal haematopoietic cells.
Parthenolide activates the mitochondrial pathway of apoptosis
Apoptotic stimuli that activate the intrinsic pathway of cell death trigger the release of cytochrome c from the mitochondria, resulting in caspase activation. 26 A change in the conformation of the proapoptotic Bax protein is thought to induce cytochrome c release and plays a key role in initiating apoptosis in CLL cells treated with conventional drugs. 27 We therefore determined whether PTL induced Bax conformation change and cytochrome c release.
Generation of the active proapoptotic form of Bax was quantified by immunoprecipitation of detergent lysates of PTL-treated CLL cells with the conformation-specific 6A7 antibody followed by Western blot analysis of the precipitates. 25 For the quantitation of cytochrome c release, we used the DDF protocol 24 to obtain cytosolic and organellar (including mitochondrial) proteins, designated as fraction (Fn) 1 and 2, respectively. Treatment of CLL cells with 10 mM PTL resulted in Bax conformation change, which was barely detectable at 2 h but clearly seen at 4 h incubation (Figure 4a ). The release of cytochrome c to the cytosol (Fn 1) followed a closely similar time course. The exclusive localization of the mitochondrial marker heat shock protein 60 (Hsp60) to Fn 2 confirms the efficient performance of the DDF protocol. In order to determine that these molecular events were not a consequence of activation of caspases, we carried out experiments using the pan-caspase inhibitor ZVAD.fmk. ZVAD almost completely blocked PTL-induced PARP cleavage (Figure 4b ) but did not affect either the Bax conformation change (Figure 4b ) or cytochrome c release (Figure 4c ) induced by PTL. Therefore, PTL-induced apoptosis rapidly engages the mitochondrial cell death pathway, involving a conformational shift of the Bax protein to the proapoptotic form and cytochrome c release to the cytosol, resulting in caspase activation.
Apoptosis induction by parthenolide is dependent on generation of reactive oxygen species
Previous studies suggested that apoptosis induction by PTL was dependent on the generation of ROS and could therefore be blocked by the free radical scavenger NAC. 16, 19 We therefore carried out experiments to determine whether a similar mechanism was operational in CLL cells. Using the fluorescent indicator CM-H 2 DCFDA, we observed that control CLL cells were heterogeneous with respect to ROS content (Figure 5a ). Incubation for 1 h with PTL resulted in the striking generation of ROS, evidenced by the appearance of a clear peak of highly fluorescent cells. N-acetylcysteine resulted in complete abrogation of PTL-induced ROS generation (Figure 5b) .
PTL-induced cytochrome c release (Figure 5c ) and Bax conformational change (Figure 5d ) were also completely prevented by NAC. Apoptosis induction by PTL, as quantified by PARP cleavage, was also strikingly blocked by NAC (Figure 5d ). Therefore, our data suggest that the generation of ROS, resulting in turn in the generation of proapoptotic Bax and subsequent cytochrome c release, plays a critical role in the induction of CLL cell apoptosis by PTL.
Actions of parthenolide on the nuclear factor-kappa B system
As an indirect measure of IKK activity in intact cells, we determined the relative intensities of bands detected by antibodies against phospho-Ikba (IkBa-P) and total IkBa (Figure 6a) . A low level of IkBa-P was detected in untreated cells. However, densitometric analysis revealed that incubation with PTL alone decreased the relative IkBa-P band intensity approximately fourfold. However, as PTL induced extensive PARP cleavage, it was important to demonstrate that this decline was not merely a consequence of caspase activation. Surprisingly, ZVAD alone induced a greater than 10-fold increase in the IkBa-P band relative to the control (Figure 6a ), which enabled us to identify a clear PTL-induced decrease in IkBa-P. The complete abolition of PTL-induced PARP cleavage by the caspase inhibitor (Figure 6a ) suggests that the decrease in IkBa-P in following PTL treatment was not a consequence of caspasemediated destruction of upstream proteins that regulate IkBa phosphorylation. Therefore, our data are compatible with the interpretation that PTL inhibits IKK in CLL cells, as described previously in other cell types. Incubation of CLL cells with PTL showed that a decline in NFkB DNA-binding activity, as quantified by an EMSA assay, was evident as early as 2 h (Figure 6b ). In contrast, PTL failed to impact on the CREB (cyclic AMP response element binding) transcription factor at up to 6 h incubation, suggesting that PTL induced a selective loss of active nuclear-localized NF-kB.
Parthenolide-induced apoptosis is apparently independent of p53 upregulation
The apoptotic pathway mediated by the p53 transcription factor plays a key role in securing the killing of malignant cells following induction of DNA damage. Impaired operation of the p53 system compromises effective treatment of CLL by conventional regimes. 28 Quantitation of induction of p53, its transcriptional target p21
CIP1 and of PARP cleavage following the generation of DNA double-strand breaks by g radiation allows the discrimination of CLL isolates with intact or impaired p53 responses. 7 The isolate designated CLL 1 in Figure 7 strongly induced both p53 and p21 CIP1 in response to radiation but not to PTL. Nevertheless, both radiation and PTL induced similar levels of PARP cleavage. Similar results were obtained using 18 additional isolates (data not shown), suggesting that killing by radiation was p53 dependent whereas the cytotoxic actions of PTL were apparently p53 independent. In contrast, CLL 2 and CLL 3 isolates (Figure 7 ) constitutively expressed p53, which was not further upregulated following irradiation, a characteriztic of cells with transcriptionally inactive p53. 7 Radiation also failed to induce p21 (CLL 3) or did so only marginally (CLL 2). Isolates CLL 2 and 3 were strikingly resistant to radiationinduced PARP cleavage, compatible with the dependence of radiation killing on an intact p53 transcriptional response. 7 In contrast, PTL readily induced PARP cleavage in CLL 2 and 3. These observations were reinforced by assessment of the percentage of apoptotic cells, identified by cell shrinkage and nuclear condensation (Figure 7) . Furthermore, the IC 50 values of CLL 1, 2 and 3 were 7.0, 8.1 and 4.3, respectively, suggesting that isolates showing evidence of p53 dysfunction were nevertheless sensitive to PTL. Similar results were obtained using four additional CLL isolates showing molecular evidence of p53 dysfunction (not shown). Taken together, the data are compatible with the interpretation that radiation-induced apoptosis of CLL cells was p53-dependent whereas killing by PTL was not.
The small molecule pifithrin a (PFT a) selectively blocks the ability of p53 to upregulate specific gene transcription. 29 Pifithrin a did not affect the upregulation of p53 in CLL cells exposed to ionizing radiation but completely blocked subsequent induction of p21 CIP1 (Supplementary Figure 2a) . Although PFT a dramatically blocked the killing of CLL cells by radiation, it failed to impact on killing by PTL (Supplementary Figure 2b  and c) . Similar results were seen in nine additional experiments (not shown), providing further evidence that PTL-induced killing of CLL cells was independent of p53-mediated transcriptional responses.
Concluding remarks
Recent studies have identified PTL as a potential agent for the treatment of myeloid leukemias, 19 hepatomas 16, 17 and cholangiocarcinoma. 18 The data here show that PTL shows a level of cytotoxicity towards CLL cells comparable to or greater than that observed in these earlier studies. The majority of isolates were induced to apoptotic death at PTL concentrations that showed only marginal actions on normal T cells and haematopoietic progenitors. This selectivity may result in a useful therapeutic window in clinical application. The potential of PTL as a therapeutic agent for CLL is further reinforced by the rapid commitment to apoptosis following brief drug exposure, the ability to kill isolates from patients belonging to either the good or poor prognostic groups or which are relatively resistant to conventional cytotoxic agents in vitro.
Mechanistic studies suggest that PTL treatment triggered the generation of ROS resulting in turn in the induction of a proapoptotic conformational switch of the Bax protein, the release of mitochondrial cytochrome c and activation of caspases. Because functional impairment of the p53-mediated apoptotic pathway is a major contributor to poor prognosis and drug resistance in CLL, 28 our data suggesting the possible p53-independence of PTL's cytotoxic mechanism is of significance. The studies summarized here therefore identify PTL as a potential therapeutic agent for the treatment of CLL.
